×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Ceftriaxone for Amyotrophic Lateral Sclerosis
therapeutic
1,111 words
KG: CEFTRIAXONE
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Ceftriaxone for Amyotrophic Lateral Sclerosis
💊
Therapeutic Info
Name
CEFTRIAXONE
Summary
EAAT2 upregulator for ALS treatment - clinical trial results
Key Genes/Proteins
GFAP
,
ALPHA_SYNUCLEIN
Related Diseases
ALEXANDER_DISEASE
Knowledge Graph
Related Hypotheses (16)
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
APOE-Dependent Autophagy Restoration
Score: 0.61
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Heterogeneous astrocyte activation states differentially imp
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Astrocyte-Mediated Microglial Memory Erasure
Score: 0.46
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE Isoform Conversion Therapy
Score: 0.44
Show 11 more
Related Analyses (18)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Show 13 more
Related Experiments (8)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
P2RY12-MTOR pathway interaction in VSMCs
exploratory · proposed · Score: 0.85
iPSC-NPC transplantation in ICH animal model
validation · proposed · Score: 0.85
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Show 3 more
See Also (1)
GFAP (Redirect)
redirect · KG edge: interacts_with
Knowledge Graph (3 edges)
CEFTRIAXONE
interacts_with
GFAP
CEFTRIAXONE
treats
ALEXANDER_DISEASE
CEFTRIAXONE
inhibits
ALPHA_SYNUCLEIN